Line of treatment for stroke according to guidelines
Reading File
Finding Sources
Searching PubMed
"ischemic stroke"[MeSH Terms] AND "treatment guideline"
Searching the Web
AHA ASA 2024 2025 ischemic stroke treatment guidelines line of treatment
Reading File
Reading Web Page
https://www.ncbi.nlm.nih.gov/books/NBK499997
Searching PubMed
"ischemic stroke" AND "management" AND "guideline"
Reading Article
PMID: 41582814
Reading File
I now have comprehensive material from the textbook (Rosen's Emergency Medicine) and the 2026 AHA/ASA guideline. Let me compile the full answer.
Lines of Treatment for Stroke - 2026 AHA/ASA Guidelines
The 2026 AHA/ASA Guideline for the Early Management of Acute Ischemic Stroke (PMID 41582814) replaced the 2018/2019 guidelines. It is the current reference standard.
Type Classification First
Stroke is broadly divided into:
- Ischemic stroke (~85%) - thrombotic, embolic, lacunar
- Hemorrhagic stroke (~15%) - intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH)
Treatment is entirely different between the two types.
ISCHEMIC STROKE
Phase 1 - Prehospital & Emergency Stabilization
- Activate stroke code / stroke team immediately
- Airway, Breathing, Circulation (ABC) - O2 only if SpO2 <94%
- IV access and rapid labs (CBC, PT/INR, aPTT, glucose, metabolic panel)
- Urgent non-contrast CT head to exclude hemorrhage before any thrombolysis
- Target door-to-needle time: <60 minutes
- BP management: Do NOT aggressively lower BP unless >185/110 mmHg AND thrombolysis is being considered (target <185/110 pre-tPA)
- Blood glucose: Treat if <60 mg/dL (IV dextrose) or persistently >180 mg/dL (target 140-180 mg/dL)
Phase 2 - Acute Reperfusion (First-Line Interventions)
1. IV Thrombolysis (IVT) - First-Line Reperfusion
Alteplase (tPA) - 0.9 mg/kg IV (max 90 mg), 10% as bolus over 1 min, remainder over 60 min
| Time Window | Recommendation |
|---|---|
| 0-3 hours | Strongly recommended (Class I, Level A) for eligible patients |
| 3-4.5 hours | Recommended for most eligible patients; some additional exclusions apply |
| 4.5-9 hours | Reasonable if MRI shows FLAIR-diffusion mismatch or perfusion imaging shows salvageable penumbra |
| Wake-up stroke / unknown onset | IVT reasonable with MRI-guided selection (FLAIR-DWI mismatch) |
Tenecteplase (TNK) - 0.25 mg/kg IV (max 25 mg), single bolus
- 2026 guidelines now recommend either alteplase or tenecteplase within the 4.5-hour window, regardless of NIHSS score, without need for advanced imaging
- TNK preferred by many centers due to simpler single-bolus dosing
Mild non-disabling stroke: IVT is NOT recommended; use dual antiplatelet therapy instead.
2. Mechanical Endovascular Thrombectomy (EVT) - First-Line for Large Vessel Occlusion (LVO)
- Proceed with EVT regardless of tPA - do not wait to observe tPA response
- Window: Within 6 hours of symptom onset - strongest evidence (Class I)
- 6-24 hours: EVT reasonable in selected patients with salvageable penumbra on perfusion imaging (DAWN/DEFUSE-3 criteria)
- Target vessel: ICA, M1 MCA, basilar artery, and select M2 occlusions
Key EVT criteria:
- Pre-stroke mRS 0-1
- Causative occlusion of ICA or proximal MCA (M1)
- Age ≥18
- NIHSS ≥6
- ASPECTS ≥6 on CT
- Treatment initiation within 6-24 hours
Phase 3 - Early In-Hospital Management
| Parameter | Target / Action |
|---|---|
| BP after tPA | <180/105 mmHg for 24 hours post-thrombolysis |
| BP without tPA | Permissive hypertension unless >220/120 mmHg; lower gradually if needed |
| Blood glucose | 140-180 mg/dL; treat hypoglycemia aggressively |
| Temperature | Treat fever (>38°C) with antipyretics |
| Cardiac monitoring | Continuous for 24 hours (detect AF); initial troponin |
| Dysphagia screening | Before any oral intake |
| DVT prophylaxis | Compression stockings; LMWH when safe to initiate |
| Early mobilization | After 24-48 hours in stable patients |
Phase 4 - Antiplatelet Therapy (Acute & Secondary Prevention)
Cardioembolic stroke (AF-related):
- Anticoagulation (NOT antiplatelet) - warfarin, apixaban, rivaroxaban, dabigatran
- Timing: typically 4-14 days post-stroke depending on stroke size
Non-cardioembolic (atherosclerotic, lacunar):
| Scenario | Regimen |
|---|---|
| Mild-moderate AIS (NIHSS ≤3, non-disabling) | Dual antiplatelet (aspirin + clopidogrel) for 21 days, then monotherapy |
| Aspirin alone | 160-325 mg within 24-48 hours; long-term 75-100 mg/day |
| Clopidogrel | Alternative if aspirin intolerant |
| TIA or minor stroke | Aspirin + clopidogrel x 21 days (Class I, Level A - based on POINT/CHANCE trials) |
Phase 5 - Secondary Prevention (Long-term)
| Risk Factor | Treatment |
|---|---|
| AF | Oral anticoagulation (DOAC preferred over warfarin) |
| Hypertension | ACE inhibitor ± thiazide diuretic; target <130/80 mmHg |
| Dyslipidemia | High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) |
| Diabetes | Glycemic control; SGLT-2 inhibitors or GLP-1 agonists for cardiometabolic benefit |
| Carotid stenosis (>70%) | Carotid endarterectomy (CEA) or stenting within 2 weeks |
| PFO + cryptogenic stroke | PFO closure in patients <60 years (Class IIa) |
| Smoking | Cessation counseling |
| Lifestyle | Diet, exercise, weight reduction |
HEMORRHAGIC STROKE
Intracerebral Hemorrhage (ICH)
- Stop any anticoagulants immediately - reversal agents:
- Warfarin: Vitamin K + 4-factor PCC (Kcentra)
- Dabigatran: Idarucizumab (Praxbind)
- Factor Xa inhibitors: Andexanet alfa
- tPA-related: Cryoprecipitate 10U IV (target fibrinogen ≥150 mg/dL), FFP
- BP control: Target SBP <140 mmHg (some guidelines 130-150)
- Labetalol 10 mg IV bolus (repeat q10-20 min, max 300 mg) or nicardipine infusion 5-15 mg/h
- ICP management: HOB 30°, osmotherapy (mannitol/hypertonic saline)
- Surgical hematoma evacuation: Considered for cerebellar hemorrhage >3 cm, or herniation; less benefit for supratentorial unless accessible
Subarachnoid Hemorrhage (SAH - Aneurysmal)
- SBP <160 mmHg (AHA/ASA) until aneurysm secured
- Secure the aneurysm: Endovascular coiling preferred over surgical clipping when both are feasible (early, within 72 hours)
- Nimodipine 60 mg q4h for 21 days (prevents vasospasm / cerebral ischemia)
- Monitor for vasospasm: TCD, CTA angiography; treat with triple-H therapy or endovascular intervention
Summary Algorithm
STROKE SUSPECTED
|
CT Head (non-contrast)
|
--------+--------
| |
ISCHEMIC HEMORRHAGIC
| |
Eligible for Reverse anticoagulation
tPA? YES -----> IV Alteplase or TNK BP control, neurosurgery consult
(0-4.5h)
|
LVO on CTA?
YES ------> EVT (Thrombectomy)
|
Antiplatelet (aspirin ± clopidogrel)
|
Secondary prevention
(statin, antihypertensives, anticoagulation if AF)
Key 2026 Updates (vs. 2018/2019):
- Tenecteplase now equal to alteplase within 4.5 hours
- Extended time window for IVT up to 9 hours with imaging guidance
- Broader EVT eligibility - extended to 24 hours with perfusion imaging
- DAPT for 21 days firmly established for minor stroke/TIA
- Pediatric stroke addressed as a dedicated section
- Simplified contraindications to thrombolysis
- Rosen's Emergency Medicine: Concepts and Clinical Practice (9780323757898), Ch. 87
- 2026 AHA/ASA Guideline for Acute Ischemic Stroke - Prabhakaran et al., Stroke 2026
- NIH StatPearls - Ischemic Stroke
This is a shared conversation. Sign in to Orris to start your own chat.